Medicine guide
Exblifep
·
- Prescription status not stated
- Antibiotics, antivirals and antifungals taken into the body
- Active substance
- Cefepime;enmetazobactam
- Made by
- Advanz Pharma Limited
- Source
- Official label
Quoted from the official source. Not yet reviewed by Mediclarum — the leaflet in your pack is authoritative.
What it is for
- Exblifep is indicated for the treatment of the following infections in adults (see sections 4.4 and 5.1): - Complicated urinary tract infections (cUTI), including pyelonephritis - Hospital-acquired pneumonia (HAP), including ventilator associated pneumonia (VAP) Treatment of patients with bacteraemia that occurs in association with, or is suspected to be associated with, any of the infections listed above. Consideration should be given to official guidance on the appropriate use of antibacterial agents.
From the official label · 2026-09-30 · European Medicines Agency
Details
| Made by | Advanz Pharma Limited |
|---|---|
| Active substance | Cefepime;enmetazobactam |
| Used in | Antibiotics, antivirals and antifungals taken into the body |
| Classification | J01DE51 · Antibiotics, antivirals and antifungals taken into the body |
| Additional monitoring ▼ | Yes — under additional monitoring (black triangle). Report suspected side effects. |
| Authorised on | 2024-03-21 |
| Last updated by the regulator | 2024-03-22 |
| EMA product number | EMEA/H/C/005431 |
Source: European Medicines Agency — medicine data · 2026-09-30 · not reviewed by a clinician
Source: European Medicines Agency (EMA). Product information as published by EMA. Reuse terms: EMA legal notice (reproduction authorised).